Optimer Pharmaceuticals Announces Presentations Of Additional Fidaxomicin Phase 3 Data At Upcoming ICAAC Annual Meeting
Source: Medical News Today
Friday 3rd September, 2010
Results from studies related to Optimer Pharmaceuticals, Inc.'s (Nasdaq: OPTR) lead developmental product candidate, fidaxomicin, will be presented at the 50th Annual Interscience Conference on Antimi... ...
Read the full story at
Medical News Today
Email this story to a friend
Have your say on this story
